Tri le, MD
Hematology & Oncology · Bedford, TXNPI 1609286756
Payments from drug & device makers
Across 88 payments — averaging $41.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Incyte Corporation$169
- AstraZeneca$166
- Gilead$164
- Bristol Myers Squibb$137
- GSK$116
- plus $786 from 22 others
What the payments were for
- Food & beverage$1,42539%
- Education$1995%
- Other$2,03056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 26 | $2,114 |
| Incyte Corporation | 4 | $169 |
| AstraZeneca(2 entities) | 4 | $166 |
| Gilead | 8 | $164 |
| Bristol Myers Squibb | 6 | $137 |
| GSK | 6 | $116 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Lilly USA, LLC | 3 | $67 |
| Merck | 3 | $61 |
| AbbVie | 2 | $53 |
| Eisai Inc. | 2 | $48 |
| Johnson & Johnson | 2 | $47 |
| Sanofi | 2 | $44 |
| Bayer | 2 | $42 |
| Immunocore Limited | 1 | $41 |
| Pfizer | 2 | $39 |
| Adaptive Biotechnologies Corporation | 1 | $34 |
| AVEO Pharmaceuticals, Inc. | 1 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Geron Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Exelixis Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $22 |
| Iovance Biotherapeutics, Inc. | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$3,653 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 28 | $623,004 |
| BrukinsaZanubrutinib | 33 | $481,500 |
| RevlimidLenalidomide | 20 | $343,608 |
| Lenalidomide | 20 | $287,262 |
| JakafiRuxolitinib Phosphate | 13 | $218,949 |
| TagrissoOsimertinib Mesylate | 14 | $214,800 |
| VenclextaVenetoclax | 12 | $186,388 |
| PromactaEltrombopag Olamine | 12 | $142,539 |
| EliquisApixaban | 122 | $140,298 |
| CabometyxCabozantinib S-Malate | 12 | $138,270 |
| XareltoRivaroxaban | 18 | $26,086 |
| Enoxaparin Sodium | 22 | $5,501 |
| Hydroxyurea | 36 | $1,191 |
| Anastrozole | 55 | $721 |
| Acyclovir | 35 | $524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $67 | $623,00428 claims |
| Bristol Myers SquibbRevlimid | $137 | $343,60820 claims |
| Incyte CorporationJakafi | $169 | $218,94913 claims |
| AstraZenecaTagrisso | $166 | $214,80014 claims |
| AbbVieVenclexta | $53 | $186,38812 claims |
| NovartisPromacta | $2,114 | $142,53912 claims |
| PfizerEliquis | $39 | $140,298122 claims |
| Exelixis Inc.Cabometyx | $24 | $138,27012 claims |
| Johnson & JohnsonXarelto | $47 | $26,08618 claims |
| Lilly USA, LLCOlanzapine | $67 | $36637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Bedford
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Drew RascoSan Antonio$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.